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HIV-1 infection generates maturational responses in overall CD4 and CD8 T cell populations in adults, with elevated expression of lytic
effector molecules perforin and granzyme B, and reduced expression of CCR7 and CD45RA. Here, we have found that these marked effects were
significantly less pronounced in children, both in terms of the skewed CCR7/CD45RA expression profile as well as the increased perforin
expression. Similar to adults, HIV-specific CD8 cells in children were largely CD27+ CD45RA− and lacked perforin. However, one pediatric
subject with late-stage infection displayed robust expansion of Gag 77–85-specific CD8 T cells which were perforin+ and lytic, but lacked
expression of CD27 and IFNγ. Our data indicate that the T cell effector maturation induced by HIV-1 infection is markedly weaker in children as
compared to adults. The data also suggest, however, that the perforin-deficient state of HIV-specific CD8 T cells in children may be reversible.
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Adaptive CD8 Tcell responses are necessary for clearance or
control of many viral infections in humans. Several observa-
tions together support a pivotal role for these cells in the partial
immune control of Human Immunodeficiency Virus-1 (HIV-1)
replication. HIV-specific CD8 T cell responses occur concur-
rently with control of peak viremia in primary infection (Borrow
et al., 1994; Koup et al., 1994; Musey et al., 1997). These
responses exert a strong selection pressure on the virus, as
evidenced by the rapid appearance of viral escape variants with
amino acid substitutions in MHC class I-presented epitopes
(Borrow et al., 1997; Goulder et al., 1997; Jones et al., 2004;
Price et al., 1997). Slow disease progression can be associated
with strong CD8 T cell responses and a healthy capacity to⁎ Corresponding author. Fax: +46 8 7467637.
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doi:10.1016/j.virol.2005.12.002express antiviral cytokines and lytic effector molecules (Klein et
al., 1995; Migueles et al., 2002; Pantaleo et al., 1995; Rinaldo et
al., 1995). Conversely, progressive HIV-1 disease and CD4 T
cell loss may be paired with progressive loss of CD8 T cell
functions (Kostense et al., 2002; Sandberg et al., 2003; Shankar
et al., 2000).
Based on the finding that HIV-specific CD8 T cells defined
by HLA-tetramers are largely low in perforin, it was suggested
that these cells may fail to mature into effector cells and they
would therefore be functionally incompetent when compared to
CD8 T cells specific for other viruses that cause chronic
infections such as Cytomegalovirus (CMV) (Appay et al., 2000;
Champagne et al., 2001). Although HIV-specific and CMV-
specific CD8 Tcells differ in surface phenotype, this may reflect
normal differences in the nature of immune responses to diverse
pathogens rather than a defect in the maturation of HIV-specific
T cells (Catalina et al., 2002; Hislop et al., 2002; Ravkov et al.,
2003; Tussey et al., 2003; van Leeuwen et al., 2002; Wills et al.,
2002; Zhang et al., 2003). However, the recent observations that
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expression in HIV-specific CD8 T cells (Migueles et al.,
2002) and a bias towards an effector-like surface phenotype in
these cells (Hess et al., 2004), suggest that the lack of effector
cell properties in HIV-specific CD8 T cells contributes to lack of
immune control of HIV-1.
It is also clear that HIV-1 affects the entire CD8 T cell
population. Several reports have indicated a close association
between the activation status of CD8 T cells and HIV-1
disease progression (Deeks et al., 2004; Giorgi et al., 1999;
Hazenberg et al., 2003; Mocroft et al., 1997), and the level of
CD8 T cell activation in early infection is an independent
predictor of the rate of CD4 T cell decline (Deeks et al.,
2004). Immune activation is likely to be directly linked toFig. 1. Differences in expression of perforin and granzyme B in peripheral blood
Comparison of 11 HIV-1-infected and 10 uninfected adult subjects (upper panels), and
to perforin and granzyme B expression in peripheral blood CD3+8+ cells assessed by
indicates P b 0.005 as determined by the t test. The panels to the right show perfor
representative out of five adult subjects and one representative out of five pediatric sub
adult subjects. Comparison of 11 HIV-1-infected and 10 uninfected adult subjects, and
in CD3+4+ cells. Mean and standard error is shown. *Indicates P b 0.05 as determimmune differentiation, and it is clear that HIV-1 infection is
accompanied by loss of naive CD4 and CD8 T cells and
expansion of T cells with down-modulated CD27 and CD28
expression (Brugnoni et al., 1996; Gruters et al., 1991;
Papagno et al., 2004; Roederer et al., 1995). In addition, HIV-
1 infection may drive the differentiation of not only HIV-
specific CD8 T cells, but also of CD8 cells specific for CMV
and EBV (Aandahl et al., 2004).
The functional status of CD4 and CD8 T cells throughout the
course of HIV-1 infection, and in particular the ability of these
cells to perform their antiviral functions through perforin-
mediated lysis of infected cells, continues to be a central issue to
the understanding of immune success and failure in HIV-1
infection. In this paper, we have compared HIV-1-infected adultT cells from adult and pediatric subjects with chronic HIV-1 infection. (A)
11 HIV-1-infected and 4 uninfected pediatric subjects (lower panels) with regard
flow cytometry. Mean and standard error is shown. *Indicates P b 0.05, and **
in expression in CD3+8+ cells stained with HLA-A2 Gag 77–85 tetramer. One
jects are shown. (B) CD4 Tcells express lytic effector molecules in HIV-infected
11 infected pediatric subjects with regard to perforin and granzyme B expression
ined by the Mann–Whitney rank sum test.
Fig. 2. State of differentiation in the CD8 and CD4 T cell compartments is less
affected by HIV-1 infection in children than in adults. PBMC from 6 HIV-1-
infected and 10 uninfected adults, and 10 infected and 4 uninfected children was
analyzed by flow cytometry with regard to CD45RA and CCR7 expression in
(A) CD3+8+ cells and (B) CD3+4+ cells, respectively. (C) Direct comparison of
CD45RA and CCR7 expression in CD3+8+ cells and CD3+4+ cells in healthy
adult subjects. Mean and standard error is shown. *Indicates P b 0.05 and
**indicates P b 0.005 as determined by the t test or the Mann–Whitney rank
sum test as appropriate.
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and expression of effector molecules. We find that while HIV-1
infection in adults drives marked maturational responses in
CD4 and CD8 T cells as assessed by CD45RA and CCR7
expression, these changes are much less pronounced in
children. There is a general enhancement in perforin and
granzyme B expression in both the CD8 and CD4 T cell
compartments of HIV-infected adult subjects compared to age-
matched uninfected controls. In children, this effect is weaker
and confined to the CD8 T cell compartment. We can confirm
the finding published previously that HIV-specific CD8 T cells
are generally low in perforin (Appay et al., 2000; Zhang et al.,
2003). However, we also present results indicating that
expansion of late-stage differentiated and lytic HIV-specific
CD8 T cells is possible even at advanced stages of disease, in
support of a model where the lack of perforin in HIV-specific
CD8 T cells represents a state of differentiation that may be
reversible. The differences we observe between adults and
children, and ability of CD8 T cells to focus on certain effector
mechanisms and to refocus during an ongoing infection are
discussed.
Results
Expression of lytic effector proteins in broad T cell populations
and antigen-specific CD8 T cells in chronically HIV-1-infected
children and adults
Direct lysis of target cells by CD8 T cells is primarily
mediated by the perforin-dependent pathway. Here, we initially
assessed the overall expression of the cytolytic effector
molecules perforin and granzyme B in peripheral blood of
pediatric and adult HIV-positive subjects, and uninfected
controls. HIV-1 infection in adults was associated with
increased expression of perforin and granzyme B in the overall
CD8 T cell compartment relative to healthy controls (P = 0.018
and P = 0.001, respectively). A similar, but less distinct pattern
was observed in children with a trend towards increased
perforin expression (P = 0.29) and significantly higher
granzyme B expression (P = 0.023) in HIV-1-infected subjects
as compared with uninfected children (Fig. 1A). Granzyme B
was more frequently expressed in CD8 Tcells than perforin, and
granzyme B+/perforin− CD8 T cells were generally CD45RO+,
in contrast to the CD45RA+ phenotype observed in perforin+
cells (data not shown). We could confirm the previous finding
that significant populations of perforin (P = 0.002) and
granzyme B (P b 0.001) expressing CD4 T cells appear in
HIV-1-infected adult subjects (Fig. 1B) (Appay et al., 2002;
Norris et al., 2004). Granzyme B was more commonly
expressed in these cells than was perforin (P b 0.001).
Interestingly, CD4 T cell populations expressing perforin and
granzyme B were significantly less prevalent in HIV-1-infected
pediatric subjects as compared to adult subjects (P = 0.006 and
P = 0.001, respectively) (Fig. 1B).
It was previously observed that HIV-specific CD8 T cells in
adult patients express little perforin protein and may be
inefficient in lysis of target cells (Appay et al., 2000; Zhanget al., 2003). We confirmed the observation that HIV-specific
CD8 T cells were mostly negative for perforin using HLA-A2
tetramers with the Gag 77–85 epitope in adults, and also found
a similar perforin-negative profile in tetramer-defined CD8 cells
in children (Fig. 1A). Thus, the generalized increase in lytic
effector cell differentiation in the peripheral blood CD8 and
CD4 T cells of HIV-1-infected adults is less pronounced in
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cells.
Analysis of naïve and memory T cell subsets defined by CD45
isoform and CCR7 in HIV-1-infected children and adults
The impact of HIV-1 infection on T cell maturation and
differentiation has been a matter of considerable debate
(Lieberman et al., 2001; Nixon et al., 2003; van Baarle et al.,
2002). Here, we examined subpopulations of CD4 and CD8 T
lymphocytes defined by their expression of CD45RA and
CCR7 in peripheral blood from HIV-1-infected adults and
children, and compared these to healthy controls (Fig. 2). As
expected (Roederer et al., 1995), HIV-1 infection in adults was
associated with reduced proportion of naive CD45RA+ CCR7+
cells in both the CD4 and CD8 T cell compartments. However,
the two compartments differed in that CD8 T cells were
enriched in CD45RA+ CCR7− late-stage differentiated cells
(Fig. 2A), whereas the CD4 T cells were predominantly biased
towards CD45RA− CCR7+ central memory and CCR7−
CD45RA− effector memory phenotypes (statistical significanceFig. 3. CD8 T cell responses to HIV-1 antigens in three pediatric patients. (A) CD
expressing HIV-1 IIIB Env, Gag, Pol, and Nef as measured in an IFNγ Elispot assay.
epitope by HLA tetramer staining and flow cytometry.indicated in figure) (Fig. 2B). Interestingly, this HIV-induced
skewing of both CD8 and CD4 T cell subsets was clearly less
pronounced in children than in adults, with significant
differences between HIV-1-infected adults and children (Figs.
2A and B). The differential bias of CD4 and CD8 Tcells seemed
to represent an elevation of the bias already present in HIV-1-
negative adult subjects (Fig. 2C). These data are compatible
with the view that HIV-1 infection drives differentiation of T
cells (Aandahl et al., 2004), and also indicate that the responses
of CD4 and CD8 T cells to the antigenic burden in HIV-1
infection differ in this regard. The maturational response of T
cells to this antigenic burden is less pronounced in children than
in adults.
Robust expansion of Gag 77–85-specific CD8 T cells can occur
late in chronic pediatric HIV-1 infection
We were next interested in assessing the function and
maturation status of T cells responding to HIV-1 antigens in
infected children. We investigated HIV-specific CD8 T cell
responses in the three pediatric subjects P59, P30 and P33 in8 T cell responses in subjects P33, P30, and P59 against vaccinia constructs
(B) Identification of CD8 T cells specific for the HLA-A2 presented Gag 77–85
Fig. 4. Robust expansion of Gag-specific CD8 T cells in a pediatric subject with
chronic HIV-1 infection and severe CD4 T cell loss. (A) Changes over time in
the frequency of CD8 T cells in PBMC from subject P59 specific for the HLA-
A2 presented Gag 77–85 epitope determined by HLA tetramer staining and flow
cytometry. (B) HIV-1 load changes with time in subject P59. (C) Absolute CD4
and CD8 cell counts over time in subject P59.
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and were HLA-A2-positive. Subject P59 was infected by
blood transfusion shortly after birth, but not diagnosed as
HIV-1-positive until age 13 when she presented with severe
immune depletion. Her initial virologic response to antire-
troviral treatment (ART) was transient, and CD4 T cell counts
remained below 200 cells/μl. The relatively long survival of
subject P59 in spite of severe CD4 T cell loss and treatment
failure prompted us to investigate the status of CD8 T cell
responses to HIV-1 in this patient. Vigorous CD8 T cell
responses to HIV-1 Pol, Env, and Nef were detected using a
recombinant vaccinia virus IFNγ Elispot assay (Fig. 3A).
However, no responses to HIV-1 Gag-expressing vaccinia
constructs were observed in P59 by this assay. Subject P33
displayed responses to all four HIV-1 gene products tested,
and P30 to all but Nef (Fig. 3A). All three subjects had
detectable populations of CD8 T cells specific for the HLA-
A2-restricted Gag 77–85 epitope (Fig. 3B). For subject P59,
this was unexpected given the lack of IFNγ production to the
Gag vaccinia construct. Over a period of several years, patient
P59 experienced an expansion of CD8 T cells specific for
Gag 77–85, up to 18.3% of total CD8 T cells (Fig. 4A). This
was accompanied by a two log10 drop in viral load to below
104 copies/ml (Fig. 4B), and decay of CD4 T cell counts from
around 200 cells/μl down to approximately 15 cells/μl,
corresponding to around 3% of PBMC (Fig. 4C). Subject P59
was before, during, and after this expansion of Gag 77–85-
specific cells on ART including a protease inhibitor. The
frequency of Gag-specific cells later declined, although
remained at elevated frequency, and viral load increased to
around 105 copies/ml while CD4 T cell counts reached a low
of 6 cells/μl. Absolute CD8 T cell numbers also declined and
reached 72 cells/μl at the last time-point analyzed. In contrast,
subjects P30 and P33 displayed stable levels of Gag 77–85-
specific cells, CD4 counts and viral loads (data not shown).
These data indicate that Gag-specific CD8 T cells maintain
the capacity for robust expansion in late-stage chronic
pediatric HIV-1 infection.
Expanded Gag 77–85-specific CD8 T cells in pediatric subject
P59 lack IFNγ, express perforin, and are cytolytic directly ex
vivo
The perforin-mediated pathway for lysis of target cells is
important for CD8 T cell-dependent immune defense against
many viruses (Harty et al., 2000). The finding that HIV-
specific CD8 T cells are generally low or negative for perforin
in chronic infection has been interpreted to indicate that this
pathway may be defective in the response to HIV-1. In contrast
to this, the expanded Gag 77–85-specific CD8 T cells in
subject P59 were predominantly perforin+ (Fig. 5). In a 51Cr-
release assay against Gag 77–85 peptide-pulsed HLA-A2+
BCL, fresh PBMC from P59 displayed significant peptide-
specific cytolytic activity ex vivo (Fig. 5). Strong ex vivo HIV-
specific cytolytic activity is not commonly observed in infected
subjects, as exemplified by our two control subjects P30 and
P33 (Fig. 5).CD8 T cells utilize several effector mechanisms other than
perforin-dependent lysis to combat viral infections, including
cytokines with antiviral effects. To further investigate the lack
of detectable IFNγ production in response to the Gag protein in
subject P59 (Fig. 3A), we used Gag 77–85 peptide as antigen in
an Elispot assay. The frequency of IFNγ expression in response
to peptide in subject P59 corresponded to only 1% of circulating
Gag 77–85-specific CD8 T cells, whereas considerably higher
numbers were obtained with subjects P30 and P33 (Fig. 6).
Inclusion of 1 ng/ml of exogenous IL-7 and IL-15 in the assay
had only a minor effect in increasing the response by P59 to the
Gag 77–85 peptide. Together, these data show that the Gag 77–
85-specific CD8 T cells that were expanded in subject P59
Fig. 5. CD8 T cells specific for Gag 77–85 in subject P59 express perforin and are cytolytic. Assessment of perforin expression (upper panels) and ex vivo cytolytic
capacity (lower panels) in CD8 T cells specific for the Gag 77–85 epitope in subjects P30, P33, and P59. Perforin expression was assessed by intracellular flow
cytometry combined with specific HLA-A2 tetramer staining. Cytolysis was determined in a 51Cr assay using BCL pulsed with Gag 77–85 peptide or an influenza
virus control peptide. For subject P59, target cells pulsed with Gag 77–85 peptide with the Yat position 3 substituted with an F, were also included. Data shown is from
week 92 of study with subject P59, which is representative out of three experiments from different time points.
122 K.A. Jordan et al. / Virology 347 (2006) 117–126expressed perforin and were lytic directly ex vivo, but expressed
almost no IFNγ.
Expanded Gag 77–85-specific CD8 T cells in pediatric subject
P59 switch to a CD27− CD45RO+ phenotype
The generally low expression of perforin in HIV-specific
CD8 T cells in adults has been suggested to associate with a
block in full effector maturation as indicated by expression of
the co-stimulatory receptor CD27 (Appay et al., 2000). Gag 77–
85-specific CD8 T cells in subject P59, as well as the
corresponding cells in subjects P30 and P33, displayed this
phenotype at the early time points measured before the
expansion of these cells took place. However, at a later time
point (week 92), these cells were CD27 negative in subject P59
(Table 1). Thus, the expansion of Gag-specific CD8 T cells was
associated with a maturational shift from CD27 positive to
CD27 negative, while they remained CD45RO+.Discussion
The long-term failure of adaptive immunity in HIV-1
infection has prompted investigators to analyze the functionality
of CD8 T cell responses in infected subjects. Suggested CD8 T
cell dysfunctions include poor cytolytic activity, low expression
of perforin, impaired cytokine production, and a maturational
block in HIV-specific cells (Appay et al., 2000; Champagne et
al., 2001; Kostense et al., 2002; Sandberg et al., 2003; Shankar
et al., 2000). We have revisited some of these aspects of T cell
biology in pediatric and adult subjects to help improve our
understanding of how these factors may influence the ability of
the immune system to control HIV-1. It is clear that HIV-1
infection drives a broad activation and differentiation of T cells
in adults, pushing an increased number of cells into late-stage
differentiation. The elevated number of T cells expressing the
cytolytic effector molecules perforin and granzyme B, and the
relative expansion of cells expressing more differentiated
Fig. 6. Poor expression of IFNγ in expanded Gag 77–85-specific CD8 T cells in
subject P59. CD8 T cell responses in subjects P33, P30, and P59 against Gag
77–85 peptide as measured in an IFNγ Elispot assay expressed as % of the
frequency observed with HLA-A2 Gag 77–85 tetramer staining. Responses
were measured using a standard IFNγ Elispot assay (white bars), and the
Amplispot assay with the addition of 1 ng/ml of exogenous IL-7 and IL-15 in
order to amplify weak responses (black bars). One representative out of six
experiments with P59 is shown.
Table 1
Maturation phenotype of HIV-1 Gag-specific CD8 T cells
Subject CD45RA CD45RO CD27 CD62L CCR7
P59 week 13 12%a 88% 90% 2% 3%
P59 week 92 16% 84% 8% n.d. n.d.
P33 10% 90% 92% 1% 5%
P30 10% 90% 95% 1% 5%
a Expression of surface receptors as indicated in Gag 77–85-specific CD3
+CD8+ cells identified using the specific HLA-A2 tetramer.
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changes in CCR7 and CD45RA expression in both CD8 and
CD4 T cell compartments in adult patients, it seems likely that
the sequence of activation and differentiation is driven by
antigens derived not only from HIV-1, but also from other
pathogens. The markedly less pronounced effector and memory
T cell maturation in HIV-1-infected children as compared to
adults could be due to the combined effect of weaker immune
responses to HIV-1 in children (Luzuriaga et al., 1995;
Sandberg et al., 2003; Scott et al., 2001), and a greater
regenerative capacity in the young immune system (Douek et
al., 1998).
Several studies have indicated that CD8 T cells specific for
HIV-1 antigens tend not to differentiate to late-stage perforin+
effector cells (Appay et al., 2000; Champagne et al., 2001;
Zhang et al., 2003). The perforin+ cells that accumulate in HIV-
1-infected adult subjects, and to a lesser extent in pediatric
subjects, may thus be specific for other antigens to which these
subjects are exposed. However, here, we have observed in one
pediatric subject that the classical perforin− CD27+ phenotype
of Gag-specific CD8 T cells can be overturned in late-stage
HIV-1 infection resulting in the expansion of perforin+ CD27−
epitope-specific CD8 T cells. The mechanism preventing this
type of effector differentiation in many infected subjects
remains unknown. However, our data suggest that it may be
possible to find a way to overcome this block and obtain full
effector differentiation of HIV-specific CD8 T cells.
The terms “function” and “dysfunction” are widely used in
the analysis of CD8 T cell responses in infectious diseases,
including HIV-1 infection. However, what is a true “dysfunc-
tion” can be very hard to establish. The phenotype of Gag-
specific CD8 T cells in subject P59 illustrates the problem of
defining a “functional” versus a “dysfunctional” response; at
early time points, the Gag-specific cells expressed littleperforin, but later on they expanded vigorously, expressed
perforin, and became lytic. These cells were very poor at
producing IFNγ, but this may represent a focusing on cytolytic
function rather than a dysfunction in IFNγ production
(Sandberg et al., 2001). The lack of IFNγ expression in these
cells is reminiscent of the “stunned” phenotype observed in
Hepatitis C virus (HCV)-specific CD8 T cells (Klenerman et al.,
2002). Another aspect that complicates the issue is that lytic
effector mechanisms may be restricted in some tissues
(Shacklett et al., 2004). An understanding of what governs
up- or down-modulation of specific functions and refocusing of
T cell function could be very valuable for the development of
effective immunotherapy. Our observations also adds to the
debate of whether full cytolytic effector differentiation of CD8
T cells and the strongest possible T cell response is always
beneficial for the HIV-1-infected host (Deeks and Walker,
2004). In subject P59, the expansion of lytic Gag-specific CD8
T cells coincided with a drop of CD4 counts down to very low
levels. It is tempting to speculate that these cytolytic CD8 T
cells, in an attempt to control HIV-1 infection, actually
contributed to the elimination of CD4 T cells in circulation.
Interestingly, in vitro experiments recently suggested that the
Gag 77–85 epitope might be helper-independent (Kan-Mitchell
et al., 2004). Such properties may allow CD8 T cells with this
specificity to persist and expand despite severe CD4 T cell loss.
In this study, we have used surface expression of CD45RA
isoform and CCR7 to characterize the differentiation status of
the CD4 and CD8 T cell compartments in HIV-1-infected adults
and children and their uninfected counterparts. The CD8 T cell
compartment of HIV-1-infected adults displayed a marked
skewing towards a late-stage CD45RA+ CCR7− phenotype,
while the CD4 T cells were biased towards a CD45RA− and
CCR7+ or CCR7-memory-like phenotype. These relative
changes in peripheral blood T cells probably represent an
expansion of memory and effector populations specific for
many different antigens, as well as loss of naive cells. In
contrast, HIV-1-infected children displayed no significant
changes in the distribution of effector and memory populations
as compared to uninfected children, perhaps indicative of a
higher regenerative capacity paired with relatively weaker
immune responses (Douek et al., 1998; Luzuriaga et al., 1995;
Sandberg et al., 2003; Scott et al., 2001). Interestingly, in adults,
it was recently observed that the majority of CD4 T cells
producing cytokines in response to HIV-1 antigens displayed
the CD45RA− CCR7− phenotype (Harari et al., 2004).
The differential bias of the CD8 and CD4 T cell compart-
ments seems to reflect an enhancement of a pattern present in
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CCR7 and preferential homing to peripheral sites in CD8 T
cells could relate to the main task of these cells, namely to
go to the periphery, scan MHC class I-presented peptides,
and eliminate infections. CD4 T cells on the other hand may
do most of their job in secondary lymphoid tissues where
MHC class II-mediated antigen presentation occurs, and
CCR7 is used to enter the T cell zones of these tissues. The
finding that CD4 T cells may start to express perforin in
response to HIV-1 infection (Appay et al., 2002; Norris et al.,
2004 and this study) is intriguing, and these cells may have a
cytolytic function in the antiviral response. Interestingly,
MHC class II-restricted killing in vivo was recently observed
in mice infected with lymphocytic choriomeningitis virus
(Jellison et al., 2005).
In this paper, we observe that the strong effector maturation
and differentiation response of CD8 T cells and CD4 T cells
driven by HIV-1 infection in adults are significantly weaker in
children. CD4 and CD8 T cells respond differently to HIV-1
infection in terms of changes in surface maturation phenotype
and this may reflect the different functions of these two major
classes of T cells. Furthermore, we identified one pediatric
subject who experienced a robust expansion of perforin+ lytic
CD8 Tcells specific for HIV-1 Gag, indicating that such effector
differentiation can occur in late-stage pediatric infection.
Interestingly, these cells where focused on cytolysis as they
produced hardly any IFNγ in response to antigen. Further
investigation into what regulates late-stage differentiation of T
cells and their focusing on certain functions remains a high
priority.
Materials and methods
Patient samples and viral load measurements
We identified eligible adult and pediatric subjects from two
existing cohorts. HIV-1-infected pediatric subjects were treated
and followed at the Jacobi Medical Center (Bronx, NY).
Median age in this group was 7 years, range 2–14 years, and
median CD4 T cell count was 834 cells/μl, range 200–1480
cells/μl. All 13 pediatric patients were on ART but experienced
varying degrees of viral suppression due to adherence problems
and drug resistance. The median viral load of these subjects was
1400 copies/ml, range 50–750,000 copies/ml. HIV-1-infected
adult subjects were from the San Francisco General Hospital
(San Francisco, CA). Nine out of 13 patients were on ART, but
only two had viral load suppressed below limit of detection. The
median CD4 T cell count of these subjects was 411 cells/μl,
range 18–911 cells/μl, and the median viral load was 2914
copies/ml, range 50–500,000 copies/ml. Uninfected adult
control subjects were healthy volunteers, and uninfected
pediatric control subjects were siblings of the infected children.
Median age in the uninfected pediatric control subjects was 6.5
years. Heparinized whole blood samples were obtained after
informed consent, based on protocols approved by local
institutional review boards. Peripheral blood mononuclear
cells (PBMCs) were isolated by Ficoll–Paque PLUS densitygradient centrifugation (Amersham Pharmacia Biotech,
Uppsala, Sweden). Plasma HIV-1 RNA was measured with
the Amplicor HIV-1 Monitor with a lower limit of quantifica-
tion at 400 copies of RNA/ml (Roche Diagnostic Systems,
Branchburg, New Jersey).
Flow cytometry and mAbs
We assessedmaturation phenotype and expression of perforin
and granzyme B in peripheral blood T cells by six-color flow
cytometry. Anti-CD62L FITC, anti-perforin FITC, purified anti-
CCR7 IgM, anti-IgM biotin, and streptavidin allophycocyanin
(APC) conjugate were purchased from BD Pharmingen, San
Jose, CA. ECD-conjugated mAbs against CD45RA and
CD45RO were from Coulter Immunotech, and anti-CD8 APC-
Cy7, anti-CD4 PE-Cy7, and anti-CD3 PE-Cy7were from Caltag
Laboratories, Burlingame, CA. 1 × 106 PBMC was first stained
with the anti-CCR7 IgM, washed, stained with anti-IgM biotin,
washed, and stained with streptavidin–APC and other mAbs to
surface antigens. After one wash, cells were plated in a 96-well
V-bottom plate, permeabilized, washed, and stained for
intracellular perforin or granzyme B. Samples were washed
three times before acquisition on a FACS Vantage SE (Becton
Dickinson, San Jose, CA) equipped with an argon laser
delivering 200 mW of power at 488 nm and a helium–neon
laser running at 5 mW and 633 nm. The six fluorescent
parameters were measured using the following band-pass filters:
FITC-525/50, PE-575/26, ECD (PE-Texas Red)-612/25, PE-
Cy7-740 LP, APC-685/80, and APC-Cy7-750 LP. Flow
cytometry data were analyzed using CellQuest software (Becton
Dickinson) or FlowJo software (Tree Star, Ashland, OR).
We identified CD8 T cells specific for HIV-1 Gag using APC
or PE-conjugated HLA-A2 tetrameric complexes refolded with
the Gag 77–85 peptide epitope (Coulter Immunotech, Mar-
seilles, France), and further phenotyped the cells using mAbs
against CD3, CD8, CD27, CD45RO, CD62L, and CCR7 (BD
Pharmingen, San Jose, CA). Ex vivo intracellular staining was
performed in the absence of any additional stimulation and in
combination with HLA-A2 tetramer staining to assess the
percentage of perforin+ tetramer+ cells. Subjects were evalu-
ated for HLA-A2 expression by staining with anti-HLA-A2
mAb (One Lambda, Canoga Park, CA). Samples were analyzed
using a FACSCalibur Instrument (BD Pharmingen) and
CellQuest (BD Pharmingen) or FlowJo software (Tree Star,
Ashland, OR).
IFNγ Elispot assay
HIV-specific CD8 T cell responses were measured using the
standard IFNγ Elispot assay as described (Larsson et al., 1999;
Sandberg et al., 2003), and the Amplispot assay which uses the
addition of 1 ng/ml exogenous IL-7 and IL-15 in order to
amplify weak responses (Chandwani et al., 2004; Jennes et al.,
2002). CD8 T cell responses were assessed using recombinant
vaccinia virus expressing HIV-1 IIIB Gag (Therion, Inc.,
Cambridge, MA) or the HLA-A*0201-restricted Gag 77–85
SLYNTVATL peptide.
125K.A. Jordan et al. / Virology 347 (2006) 117–126Statistical analysis
The flow cytometry data obtained were analyzed by
descriptive statistics, t test, the Mann–Whitney rank sum test,
the paired t test, and the signed rank test, as appropriate using
Sigma Stat software (SPSS, Chicago, IL).
CTL assay
CTL activity was measured in a standard 51Cr-release assay.
Briefly, Gag 77–85 SLYNTVATL peptide-coated, Gag 77–85
SLFNTVATL mutant peptide-coated, or Influenza virus M1
58–66 GILGFVFTL control peptide-coated B cell line (BCL)
target cells were prepared by incubating cells with 10 μM
peptide or in the absence of peptide for 1 h at 37 °C. These cells
were next labeled with 10 μl 10 mCi/ml 51Cr for 1 h at 37 °C.
Titrated numbers of effector cells were incubated with 3 × 103
51Cr-labeled target cells for 4 h at 37 °C, 5% CO2. After
incubation, released radioactivity was measured and specific
lysis was calculated according to the formula: % specific
release = ((experimental release-spontaneous release) / (maxi-
mum release-spontaneous release)) × 100.Acknowledgments
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